History of the Development of Antiemetic Guidelines at Mayo Clinic Rochester Charles L. Loprinzi, MD, Steven R. Alberts, MD, Bradley J. Christensen, BS Pharm, Lorelei J. Hanson, RN, David R. Farley, MD, Joan K. Broers, RN, Donna L. Betcher, RN, Robert E. Grady, MD, Peter A. Southorn, MD, Todd M. Johnson, PharmD, Edith A. Perez, MD Mayo Clinic Proceedings Volume 75, Issue 3, Pages 303-309 (March 2000) DOI: 10.4065/75.3.303 Copyright © 2000 Mayo Foundation for Medical Education and Research Terms and Conditions
Figure 1 Mean episodes of emesis per person per day for patients receiving grade 3 emetogenic chemotherapy (left) or grade 4 emetogenic chemotherapy (right). Patients with 5 or more episodes of emesis per day were classified as having 5 emesis episodes for that day. Mayo Clinic Proceedings 2000 75, 303-309DOI: (10.4065/75.3.303) Copyright © 2000 Mayo Foundation for Medical Education and Research Terms and Conditions
Figure 2 Percentage of patients with complete emesis control (no emetogenic episodes) per day for those receiving grade 3 emetogenic chemotherapy (left) or grade 4 emetogenic chemotherapy (right). Mayo Clinic Proceedings 2000 75, 303-309DOI: (10.4065/75.3.303) Copyright © 2000 Mayo Foundation for Medical Education and Research Terms and Conditions